Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis

Hinojosa‐Azaola, Andrea; Jiménez-González, Ariadna; Alcocer-Castillejos, Natasha

doi:10.1007/s00296-017-3904-1

Cited by 17 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corresponding funnel plot shown in supplementary materials however, report a significant association between PHQ-9 and fatigue (r = 0.73, p < 0.05). Hinojosa-Azaola et al also found an association between HADS and fatigue (r = 0.48, p = 0.01) among AAV patients [27]. When they dichotomised HADS scores (threshold > 7), those with depression or anxiety had more steroid use (prednisolone ≥ 10 mg/ day; OR 6.65, 95% CI 1.37-32) than those without.…”

Section: Associations Between Depression and Disease Outcomesmentioning

confidence: 89%

“…Hajj-Ali et al also reported a higher prevalence of depression among GPA patients when compared to the general population (22 vs 7.6%; p < 0.001) [13]. Hinojosa-Azaola et al reported a numerically higher prevalence of depression in AVV patients (9%) than RA (4%) and CKD (1%) controls, although this was not statistically significant (p = 0.29) [27]. Basu et al found no significant difference in depression (BDI ≥ 13; AAV 15% vs primary care controls 21%; p = 0.50) [19].…”

Section: Depression Compared Between Psv and Controlsmentioning

confidence: 94%

See 1 more Smart Citation

The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Objective To describe the prevalence of depression among patients with primary systemic vasculitides (PSV); compare prevalence according to vasculitis type and against controls; and examine the impact of depression on PSV outcomes. Methods We searched Medline, PubMed, Scopus and Web of Science using a predefined protocol in accordance with PRISMA guidelines. We included all studies that reported the prevalence or impact of depression in PSV. We also included polymyalgia rheumatica (PMR) given its association with giant cell arteritis (GCA). Meta-analyses of prevalence estimates were performed using random-effects models and reported as percentages (95% confidence interval). Results We reviewed a total of 15 studies that described the prevalence of depression, categorised into small (n = 10) and large vessel vasculitis (n = 7). Pooled prevalence estimate for depression in a small vessel (predominantly ANCA-associated) vasculitis was 28% (95% CI 20-38%) with significant heterogeneity (I 2 = 93%). Depression prevalence in large-vessel vasculitis (Takayasu and GCA/PMR) was 24% (95% CI 17-34%), again with significant heterogeneity (I 2 = 96%). One study reported 56% prevalence of depression in medium vessel disease. The prevalence of depression in small vessel vasculitis was higher than healthy controls. In these patients, depression and depressive symptoms were associated with poorer quality of life, adherence, and work disability, but not disease activity or damage. Conclusion Depression is highly prevalent among patients with primary systemic vasculitis and associated with poorer outcomes across a range of measures in studies of small vessel disease. Further studies are needed for depression in medium and large vessel vasculitides.

show abstract

Section: Associations Between Depression and Disease Outcomesmentioning

confidence: 89%

Section: Depression Compared Between Psv and Controlsmentioning

confidence: 94%

The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This healthcare burden was expected in FVG considering the becoming into a chronic disease of AAV, thanks to improvements in treatment. Emerging evidence in other studies [10,33] is the negative effect on patients' physical and mental quality of life (QoL) of AAV, comparable to other chronic diseases. Current vasculitis disease assessment tools (BVAS v3 and VDI) are only weakly correlated with measures and variations of QoL [34,35].…”

Section: Discussionmentioning

confidence: 99%

Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases

Quartuccio

Treppo

Valent³

et al. 2020

Intern Emerg Med

View full text Add to dashboard Cite

ANCA-associated vasculitides (AAV) comprise a group of systemic vasculitides characterized by inflammation of small-sized blood vessels leading to multi-organ involvement. The worldwide annual incidence of AAV ranges from 1.2 to 3.3 cases per 100 000 individuals with a prevalence of 4.6-42.1 cases per 100 000 individuals. The prevalence of AAV is geographically heterogeneous; therefore, regional epidemiological studies can be more informative to improve health care systems. Even though clinicians are aware that the healthcare burden and the risk of hospitalization of AAV appear high, data on hospitalization and cost of illness due to AAV are still scarce or even lacking. This study aims to characterize the economic burden of AAV in Friuli Venezia Giulia (FVG), Italy. Thus, a retrospective study was conducted through the integration of many administrative health databases of the FVG as the source of information. From data integration, we estimated that more than two-thirds of AAV patients showed at least one hospitalization in their medical history, most frequently caused by the disease itself or superimposed infections. Around 10% of patients developed end-stage renal disease. In an 8-year follow-up, the overall healthcare cost was € 1,215,078, corresponding to € 6,168 patient-year. ANCA-positive patients showed much higher costs than ANCA-negative patients did. Overall, AAV are rare diseases, but imply very high healthcare costs. Early diagnosis and optimal treatment probably still remain unmet needs for AAV.

show abstract

“…Patients included in the present study participated in a crosssectional comparison analysis conducted to assess patient and physician perspectives on HRQOL in patients with AAV (Hinojosa-Azaola et al, 2018). Inclusion criteria were patients >18 years old with established diagnosis of AAV (GPA, MPA, or RLV) according to the American College of Rheumatology (ACR) 1990 or the definition by the 2012 Chapel Hill Consensus (Jennette et al, 2013;Leavitt et al, 1990).…”

Section: Study Patientsmentioning

confidence: 99%

No Difference in Cognitive Dysfunction Among Patients with ANCA-Associated Vasculitis, Rheumatoid Arthritis or Chronic Kidney Disease

Alcocer-Castillejos

Jiménez-González

Hinojosa‐Azaola

2019

J Int Neuropsychol Soc

Self Cite

View full text Add to dashboard Cite

Objective: To characterize cognitive function in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) in comparison with other chronic conditions, and to investigate its association with disease activity, and other psychological factors. Methods: Cross-sectional study including patients with AAV, rheumatoid arthritis (RA) (n = 30), and chronic kidney disease (CKD) (n = 29). Patients underwent a standardized neuropsychological battery (NEUROPSI). Sleep quality, fatigue, depression, and anxiety levels were assessed. Results: A total of 60 patients with AAV were included, median age of 54 years, and disease duration of 5.6 years. Prevalence of cognitive dysfunction (CD) in AAV patients was similar to RA and CKD (35%, 40%, and 39.3%, respectively, p = .88). When AAV patients with (n = 21) and without (n = 39) CD were compared, significantly more patients with CD had high disease activity (67% vs. 31%, p = .009). Abnormal performance was more frequent in the executive functions in the three groups (45% AAV, 51.7% RA, and 50% CKD), followed by language (25%, 13.8%, and 25%, respectively). Verbal and visual attentional tests were more frequently impaired in patients from the CKD group (p = .021), and psychomotor functions were more frequently affected in AAV patients (p < .05). Hospital Anxiety and Depression Scale (HADS) total score (especially anxiety) was higher in patients with memory impairment than in those with normal memory function (M = 6.79, SD = 4.53 vs. M = 4.5, SD = 3.6, p < .01). Neither Sleep Quality Index nor fatigue scale scores differed between those cognitively impaired and not impaired. Conclusions: No statistically significant differences were found in the frequency of CD among the three clinical populations. (JINS, 2019, 25, 595–602)

show abstract

Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis

Cited by 17 publications

References 36 publications

The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis

The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis

Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases

No Difference in Cognitive Dysfunction Among Patients with ANCA-Associated Vasculitis, Rheumatoid Arthritis or Chronic Kidney Disease

Contact Info

Product

Resources

About